Previous 10 | Next 10 |
Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting PR Newswire SALT LAKE CITY , March 18, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company...
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on March 29 PR Newswire SALT LAKE CITY , March 18, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SER...
The following slide deck was published by Sera Prognostics, Inc. in conjunction with this event. For further details see: Sera Prognostics (SERA) Investor Presentation - Slideshow
SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES PR Newswire SALT LAKE CITY , March 3, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by prov...
SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE PR Newswire SALT LAKE CITY , Feb. 17, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal...
SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES PR Newswire SALT LAKE CITY , Feb. 7, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health b...
Sera Prognostics (SERA +3.7%) has signed an agreement with MultiPlan to join its PHCS and MultiPlan Networks to widen the patient access to the company’s PreTRM Test, a blood-based biomarker test to predict spontaneous preterm birth. PreTRM Test allows the clinicians to accurately iden...
SERA PROGNOSTICS ANNOUNCES NEW AGREEMENT WITH MULTIPLAN, EXPANDING PATIENT ACCESS TO THE PRETRM® TEST PR Newswire SALT LAKE CITY , Feb. 1, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving mater...
SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX PR Newswire SALT LAKE CITY , Dec. 15, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregna...
Sera Prognostics Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm Birth - New Assigned Rate Further Validates the Commercial Value of the PreTRM® Test - PR Newswire SALT LAKE CITY , Dec 2, 2021 /PRN...
News, Short Squeeze, Breakout and More Instantly...
Sera Prognostics Inc. Company Name:
SERA Stock Symbol:
NASDAQ Market:
Sera Prognostics Inc. Website:
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024 PR Newswire SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA)...
Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial PR Newswire Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-R...
2024-07-06 13:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...